Search Results for "Drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug. Results 2471 to 2480 of 2581 total matches.

Screening for Melanoma

   
The Medical Letter on Drugs and Therapeutics • Sep 05, 2011  (Issue 1372)
OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS The Medical Letter® On Drugs ...
In the absence of randomized studies demonstrating an impact on mortality, the US Preventive Services Task Force (USPSTF) has found the evidence insufficient to recommend a routine whole-body examination for melanoma and other skin cancers.
Med Lett Drugs Ther. 2011 Sep 5;53(1372):72 |  Show IntroductionHide Introduction

An Imaging Agent for Amyloid

   
The Medical Letter on Drugs and Therapeutics • Jul 09, 2012  (Issue 1394)
The Medical Letter® On Drugs and Therapeutics Volume 54 (Issue 1394) July 9, 2012 ...
The FDA has approved florbetapir F18 (flor bay´ ta pir; Amyvid – Lilly), an intravenous radioactive diagnostic agent used with positron emission tomography (PET) scans, to estimate β-amyloid neuritic plaque density in adults being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline.
Med Lett Drugs Ther. 2012 Jul 9;54(1394):54-5 |  Show IntroductionHide Introduction

In Brief: Meningococcal Vaccine for Infants

   
The Medical Letter on Drugs and Therapeutics • Nov 11, 2013  (Issue 1429)
The Medical Letter® On Drugs and Therapeutics Volume 55 (Issue 1429) November 11, 2013 ...
Rates of meningococcal disease are highest in infancy, but until recently no meningococcal vaccine was approved for use in this age group. MenHibrix (GSK), a new conjugate vaccine that protects against Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b (Hib), has been approved by the FDA for use in infants ≥6 weeks old and Menveo, a meningococcal vaccine already approved for patients ≥2 years old that protects against serogroups A, C, Y, and W-135, is now approved for use in infants ≥2 months old.SEROGROUPS — Five major serogroups of N. meningitidis, A, B, C,...
Med Lett Drugs Ther. 2013 Nov 11;55(1429):92 |  Show IntroductionHide Introduction

In Brief: Suspension of Johnson & Johnson COVID-19 Vaccine Lifted (online only)

   
The Medical Letter on Drugs and Therapeutics • May 17, 2021  (Issue 1624)
.6 1. In brief: Johnson & Johnson COVID-19 vaccine suspended. Med Lett Drugs Ther 2021 May 3 (epub ...
On April 23, 2021, on advice from the Advisory Committee on Immunization Practices (ACIP), the FDA and CDC recommended that use of the Johnson & Johnson adenovirus-based COVID-19 vaccine resume despite its association with development of thrombosis with thrombocytopenia syndrome (TTS). Administration of the vaccine had been paused on April 13 because of 6 reports of TTS, but after completing a data review that identified a further 9 cases associated with the formulation, the agencies concluded that the benefits of the vaccine outweighed its risks. About 7.98 million doses of the...
Med Lett Drugs Ther. 2021 May 17;63(1624):e1 |  Show IntroductionHide Introduction

Revakinagene Taroretcel (Encelto) – A Gene Therapy for Idiopathic Macular Telangiectasia (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 28, 2025  (Issue 1727)
vision loss. Antithrombotic drugs should be stopped temporarily before implantation of Encelto ...
Revakinagene taroretcel-lwey (Encelto – Neurotech), an intravitreal allogeneic cell-based gene therapy, has been approved by the FDA for treatment of idiopathic macular telangiectasia type 2 in adults. It is the first treatment to be approved in the US for this indication.
Med Lett Drugs Ther. 2025 Apr 28;67(1727):e74   doi:10.58347/tml.2025.1727f |  Show IntroductionHide Introduction

Influenza Vaccine for 2024-2025

   
The Medical Letter on Drugs and Therapeutics • Sep 16, 2024  (Issue 1711)
with permission by First Databank, Inc. All rights reserved. ©2024. www.fdbhealth.com/policies/drug-pricing ...
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2024-2025 season are listed in Table 2.
Med Lett Drugs Ther. 2024 Sep 16;66(1711):145-50   doi:10.58347/tml.2024.1711a |  Show IntroductionHide Introduction

The Viralizer For The Common Cold

   
The Medical Letter on Drugs and Therapeutics • Jan 27, 1989  (Issue 784)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Recently, full-page advertisements have appeared in the New York Times and other newspapers promoting the Viralizer (Viral Response Systems, Greenwich, CT), a heated nebulizer-sprayer device marketed for treatment of colds, sore throats, allergy and sinusitis symptoms. The device is available without a prescription for about $30 to $40.
Med Lett Drugs Ther. 1989 Jan 27;31(784):8 |  Show IntroductionHide Introduction

Pallidotomy for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Dec 06, 1996  (Issue 989)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Ablation of the globus pallidus, an old treatment for Parkinsons disease, is being tried again, using more refined stereotactic techniques, improved brain imaging and new methods for recording neuronal activity (CW Olanow, Ann Neurol, 40:341, September 1996).
Med Lett Drugs Ther. 1996 Dec 6;38(989):107 |  Show IntroductionHide Introduction

Cosmetic Phalloplasty

   
The Medical Letter on Drugs and Therapeutics • May 24, 2004  (Issue 1183)
have occurred. Medical Letter consultants advise against them. 44 The Medical Letter ® On Drugs ...
Some patients may be asking healthcare providers about the surgical techniques to enlarge the penis that are widely promoted on the Internet. Phalloplasty was first used to treat traumatic or surgical amputation (for cancer), epispadias and Peyronie's disease (JP Yurkanin et al, J Urol 2001; 166:1769).
Med Lett Drugs Ther. 2004 May 24;46(1183):44 |  Show IntroductionHide Introduction

New Treatments for Keratoconus

   
The Medical Letter on Drugs and Therapeutics • May 30, 2011  (Issue 1365)
The Medical Letter® On Drugs and Therapeutics Volume 53 (Issue 1365) May 30, 2011 ...
Keratoconus is a fairly common, progressive, noninflammatory, corneal-thinning disorder in which the cornea has a conical shape. Rigid gas permeable (RGP) contact lenses or corneal transplantation are effective treatments, but intracorneal ring segments and collagen cross-linking procedures offer some new alternatives in the management of the disease.
Med Lett Drugs Ther. 2011 May 30;53(1365):43-4 |  Show IntroductionHide Introduction